NCT00938392View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly

PHASE3CompletedINTERVENTIONAL
Enrollment

726

Participants

Timeline

Start Date

July 30, 2009

Primary Completion Date

October 5, 2009

Study Completion Date

October 5, 2009

Conditions
Influenza
Interventions
BIOLOGICAL

GSK investigational FluNG vaccine GSK2186877A, aged lot

Single dose, intramuscular injection

BIOLOGICAL

GSK investigational FluNG vaccine GSK2186877A, fresh lot

Single dose, intramuscular injection

Trial Locations (6)

50106

GSK Investigational Site, Tartu

Unknown

GSK Investigational Site, Tallinn

811 03

GSK Investigational Site, Bratislava

814 66

GSK Investigational Site, Bratislava

841 04

GSK Investigational Site, Bratislava

900 24

GSK Investigational Site, Veľký Biel

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00938392 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly | Biotech Hunter | Biotech Hunter